SPTBN1 abrogates renal clear cell carcinoma progression via glycolysis reprogramming in a GPT2-dependent manner.

Jiajin WuChenkui MiaoYuhao WangSongbo WangZhongyuan WangYiyang LiuXiaoyi WangZengjun Wang

Published in: Journal of translational medicine (2022)

Our research demonstrated that SPTBN1 is significantly down-regulated in ccRCC. SPTBN1 knockdown promotes ccRCC progression via activating GPT2-dependent glycolysis. SPTBN1 may serve as a therapeutic target for the treatment of ccRCC.

Keyphrases

signaling pathway
combination therapy
replacement therapy